New Immunotherapy Plus Chemo Before Surgery for Head and Neck Cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This study tests a new combination of an immunotherapy drug (AK112) with chemotherapy before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes for patients who have not been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have squamous cell carcinoma in your mouth, throat, voice box, or lower throat that can be removed with surgery.
- You have not received any previous treatment for this cancer.
- You are in good enough health to undergo surgery and treatment, with normal blood counts and organ function.
- You do not have active autoimmune disease, serious infections, or unstable heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests an immunotherapy drug (anti-PD-1) given before surgery for head and neck cancer that has come back or spread. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests whether giving a combination of immunotherapy drugs (pembrolizumab, N-803, and possibly PD-L1 t-haNK cells) before surgery can help treat head and neck cancer that has not been treated yet. It is for people whose cancer is p16-negative (a specific marker) and is at an intermediate or high risk of coming back.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
Hear when a new Neoadjuvant Therapy of Operable Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.